FIGURE 1

Aerobic and anaerobic susceptibility results for 114 isolates of *P. aeruginosa* from cystic fibrosis patients.

Antibiotic	Aerobic			Anaerobic (+ 1% KNO_3)			Fold In crease in Geometric Mean in Anaerobic Conditions	Isolates with >4-fold MIC Increase in Anaerobic Conditions (%)
	$MIC_{50/90}$	MIC Range	Geo Mean	$MIC_{50/90}$	MIC Range	Geo Mean		
Levofloxacin	2 / 16	≤0.03 - 32	1.7	4 / 16	≤0.125 - 128	2.4	1.4	4
Tobramycin	1 / 32	0.06 - >32	1.2	4 / 128	0.5 - >128	8.4	6.7	66
Amikacin	8 / >128	≤0.125 - >128	7.9	16 / >128	1 - >128	32.3	4.1	46
Aztreonam	4 / 128	≤0.125 - >128	3.9	64 / >128	≤0.125 - >128	22.3	5.7	42

MIC results are reported as mg/L.

Geo mean, geometric mean of the MIC distribution.

FIGURE 2A

P. aeruginosa **aerobic and anaerobic MIC distributions for levofloxacin (LVX).**




FIGURE 2B

P. aeruginosa **aerobic and anaerobic MIC distributions for tobramycin (TOB).**




FIGURE 2C

P. aeruginosa **aerobic and anaerobic MIC distributions for amikacin (AMK).**




FIGURE 2D

P. aeruginosa **aerobic and anaerobic MIC distributions for aztreonam (ATM).**




FIGURE 3A

Mean log CFU/ml of *P. aeruginosa* over time for strain PAM1020, wild-type.




FIGURE 3B

Mean log CFU/ml of *P. aeruginosa* over time for strain PAM1032, *nalB*.




FIGURE 3C

Mean log CFU/ml of *P. aeruginosa* over time for strain PAM1481 *na1B gyrA.*




FIGURE 3D

Mean log CFU/ml of *P. aeruginosa* over time for strain PAM1573, *nalB gyrA* (Thr83Ile).

